Abstract
The HER-2/neu proto-oncogene is frequently amplified or overexpressed in human breast and ovarian cancers, and is significantly correlated with shorter survival. We have previously reported that the adenovirus type 5 early region 1A (E1A) gene product can repress HER-2/neu overexpression by repressing HER-2/neu promoter activity, and suppress the tumorigenic potential of HER-2/neu-overexpressing ovarian cancer cells. To examine E1A tumor suppressor function in breast cancer, we transduced E1A in vitro by adenovirus into both HER-2/neu-overexpressing and low expressing human breast cancer cell lines. In HER-2/neu-overexpressing cells, E1A greatly inhibited tumor cell growth in vitro. However, in HER-2/neu low expressing cancer cell lines, E1A had no significant effect on cell growth in culture medium. To test the therapeutic efficacy of E1A, we used both adenovirus-mediated and cationic liposome-mediated E1A gene delivery systems in an orthotopic breast cancer animal model. An advanced breast cancer model was established by inoculation of HER-2/neu-overexpressing human breast cancer cells in mammary fat pad and treated by local injections of either replication-deficient adenovirus expressing E1A, Ad.E1A(+) or a liposome-E1A DNA complex. As controls, mice bearing tumors were also treated with Ad.E1A(−) which is virtually the same adenovirus as Ad.E1A(+) except that E1A is deleted, a liposome-E1A frame-shift mutant DNA complex, or just PBS. In mice bearing a HER-2/neu-overexpressing breast cancer cell line, E1A delivered either by adenovirus or liposome significantly inhibited tumor growth and prolonged mouse survival compared with the controls. In fact, 60 – 80% of E1A-treated mice lived longer than 2 years versus only 0 – 20% of control mice (P<0.05). Western blot analysis showed that E1A protein was expressed in tumor tissue and immunohistochemical analysis showed that HER-2/neu p185 protein expression was suppressed. Taken together, our results indicated that both adenovirus and cationic liposome delivery systems were effective in transfering E1A gene for tumor suppression in a HER-2/neu-overexpressing breast cancer model.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
This research was supported by DHHS Grants R01-CA58880 and R01-CA60856, Army Breast Cancer Grant 17-94-J4315, Nelly Connally Breast Cancer Fund (to M-C Hung), CA59327, CA64654, DK44935 and HL50256 (to L Huang)
Rights and permissions
About this article
Cite this article
Chang, J., Xia, W., Shao, R. et al. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer. Oncogene 14, 561–568 (1997). https://doi.org/10.1038/sj.onc.1200861
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1200861
- Springer Nature Limited
Keywords
This article is cited by
-
ARD1 contributes to IKKβ-mediated breast cancer tumorigenesis
Cell Death & Disease (2018)
-
Crosstalk between Arg 1175 methylation and Tyr 1173 phosphorylation negatively modulates EGFR-mediated ERK activation
Nature Cell Biology (2011)
-
Adenovirus 5 E1A enhances histone deacetylase inhibitors-induced apoptosis through Egr-1-mediated Bim upregulation
Oncogene (2010)
-
E1A inhibits the proliferation of human cervical cancer cells (HeLa cells) by apoptosis induction through activation of HER-2/Neu/Caspase-3 pathway
Medical Oncology (2008)
-
ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation
Nature Cell Biology (2008)